RM-MET / Metabolic and incretin signalling
Survodutide
Also known as: BI 456906 · BI456906
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Survodutide is the nonproprietary name used for BI 456906, a modified dual glucagon/GLP-1 receptor agonist.
Evidence position
Published randomized obesity and MASH studies support Grade B. Trial formulation, dose escalation and population remain material parts of that evidence.
What the record does not establish
The literature does not authenticate a vendor sample or show that a separately sourced material matches BI 456906 in sequence, modification, strength or formulation.
Sources
- 01Survodutide compound recordPubChem
- Shows
- Registry identity, formula, molecular properties and BI 456906 synonyms
- Does not show
- Chemical identity does not establish efficacy or lot quality
- 02A phase 2 randomized trial of survodutide in MASH and fibrosisPubMed
- Shows
- Human randomized interventional evidence with histologic outcomes
- Does not show
- Trial results apply to the protocol-defined study product and population
- 03Survodutide obesity dose-finding studyClinicalTrials.gov
- Shows
- Official intervention aliases, design, arms and posted study record
- Does not show
- Registration is not approval or lot verification
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Survodutide
- CID
- 168429725
- Formula
- C192H289N47O61
- Mass
- 4232
PUBMED / FOUND RECORDS
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine / 2024 Jul 25PMID 38847460 / DOI 10.1056/NEJMoa2401755
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.Diabetes care / 2024 Nov 1PMID 38843460 / DOI 10.2337/dci24-0003
- Emerging pharmacotherapies for obesity: A systematic review.Pharmacological reviews / 2025 JanPMID 39952695 / DOI 10.1124/pharmrev.123.001045
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.The lancet. Diabetes & endocrinology / 2024 MarPMID 38330987 / DOI 10.1016/S2213-8587(23)00356-X
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.Molecular metabolism / 2022 DecPMID 36356832 / DOI 10.1016/j.molmet.2022.101633
CLINICALTRIALS.GOV / FOUND RECORDS
- A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)COMPLETED / PHASE3 / Boehringer IngelheimNCT06309992 / DIRECT intervention MATCH: Survodutide
- LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisRECRUITING / PHASE3 / Boehringer IngelheimNCT06632457 / DIRECT intervention MATCH: Survodutide
- A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightCOMPLETED / PHASE2 / Boehringer IngelheimNCT04667377 / DIRECT intervention MATCH: Survodutide
- A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityCOMPLETED / PHASE1 / Boehringer IngelheimNCT06200467 / DIRECT intervention MATCH: Survodutide
- A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the BodyCOMPLETED / PHASE1 / Boehringer IngelheimNCT06772532 / DIRECT intervention MATCH: Survodutide